NMD Pharma A/S, a clinical-stage biotech company dedicated to developing novel and improved treatments for patients living with neuromuscular diseases, a...
Eisai Co., and Biogen announced that the U.S. Food and Drug Administration (FDA) has accepted Eisai’s Supplemental Biologics License Applicat...
The CE-IVD marked QIAstat-Dx Respiratory SARS-CoV-2 Panel is available in Malaysia expanded to 23 pathogens, now includes Chlamydophila pneumoniae&nb...
Recommendation for adults with uncontrolled COPD with raised blood eosinophils based on data from two landmark Phase 3 trials demonstrating Dupixent sign...
Stryker a global leader in medical technologies, announced that the first surgeries using the Gamma4 Hip Fracture Nailing System in Europe were completed...
Helsinn Group (“Helsinn”), a global pharmaceutical company with a track record of over forty-five years of commercial execution and a strong ...
Eisai Co., Ltd. (CEO: Haruo Naito) and Biogen Inc. (CEO: Christopher A. Viehbacher) announced that the Ministry of Food and Drug Safety (MFDS) in South K...
Transaction to include felzartamab, a potential first-in-class therapeutic candidate with promise as a pipeline-in-a-product across a range of immune-m...
May is Hepatitis Awareness Month, the perfect time for individuals to talk to their health care providers about hepatitis vaccinations. Hepatitis is an inf...
bioLytical Laboratories Inc. announced today the immediate availability of its INSTI® HCV Antibody Test in the Australian market. The INSTI He...
Genentech, a member of the Roche Group announced positive results from the Phase Ib clinical trial of CT-388, a dual GLP-1/GIP receptor agonist being...
BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma ...
Baxter International Inc. (NYSE: BAX), a pioneer in nutrition therapy, proudly announces the United States Food and Drug Administration (FDA) approval of a...
Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated today that the National...
© 2024 Biopharma Boardroom. All Rights Reserved.
